426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg

Publication | Closed Access

DOI

Citations

References

2020

Year

Marcia S. Brose, Y. Panaseykin, Bhavana Konda, Christelle de la Fouchardière, Brett Hughes, Andrew G. Gianoukakis, Y.J. Park, I. Romanov, Monika K. Krzyzanowska, T. Binder,

Annals of Oncology

Nuclear MedicineOncologyMedicineThyroid DiseasePhase Ii StudyA MulticenterRadiopharmaceutical TherapyPharmacotherapyCancer TreatmentThyroid HormonePharmacologyRadiation OncologyThyroid CancerCancer Research